ストックスクリーナーアプリを入手
74.98
2.23%
-1.71
アフターアワーズ：
74.98
Kymera Therapeutics Inc (KYMR) 最新ニュース
Why Kymera Therapeutics Inc. stock is trending among retail traders2025 Price Momentum & AI Powered Buy/Sell Recommendations - ulpravda.ru
Will Kymera Therapeutics Inc. stock maintain growth storyWeekly Trade Report & Step-by-Step Trade Execution Guides - ulpravda.ru
Why Kymera Therapeutics Inc. stock could see breakout soonJuly 2025 Selloffs & Weekly Consistent Profit Watchlists - ulpravda.ru
Kymera Therapeutics (NASDAQ:KYMR) Nasdaq Composite ETF Protein Regulation - Kalkine Media
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Is Kymera Therapeutics (KYMR) Balancing Pipeline Ambition and Execution Risk After New KT-621 Milestone? - Yahoo Finance
Kymera Advances KT-621 Into Mid-Stage Asthma Trial, Setting Up a New Catalyst for KYMR Investors - TipRanks
Kymera jumps on early-stage data for eczema candidate KT-621 - MSN
Kymera Therapeutics, Inc. (KYMR) Stock Analysis: A Biotech Leader with a 59.70% Potential Upside - DirectorsTalk Interviews
Kymera Therapeutics (KYMR) Downgraded by Wolfe Research | KYMR S - GuruFocus
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 - The Manila Times
Kymera Therapeutics CEO to unveil 2026 milestones at JPMorgan event - Traders Union
Wolfe Research downgrades Kymera Therapeutics stock rating on lack of catalysts - Investing.com UK
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? - sharewise.com
Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next - TechStock²
Kymera Therapeutics (KYMR) stock drops 6.6% to start 2026 as insider sale filing stays in focus - ts2.tech
KYMR Stock Falls -14% With A 7-day Losing Spree On Significant Insider Selling - Trefis
Kymera Therapeutics stock slides nearly 7% after CEO share-sale filing — what KYMR investors watch next - ts2.tech
Kymera Therapeutics (NASDAQ:KYMR) Trading Down 4.3%What's Next? - MarketBeat
Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks - Investing.com
Kymera Therapeutics (KYMR) Sees 4% Drop in Stock Price - GuruFocus
Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks - MarketBeat
The Technical Signals Behind (KYMR) That Institutions Follow - Stock Traders Daily
Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 30,000 Shares - MarketBeat
Kymera Therapeutics Insider Sold Shares Worth $2,341,939, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics (NASDAQ: KYMR) CEO reports option exercise and share sale - Stock Titan
Kymera Therapeutics Earnings Notes - Trefis
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching - ts2.tech
Kymera Therapeutics announces results from BroADen Phase 1b trial of KT-621 - MSN
Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating - MSN
Kymera draws upgrades after early-stage data for anti-inflammatory agent - MSN
B. Riley Securities Maintains Kymera Therapeutics (KYMR) Buy Recommendation - Nasdaq
Why Kymera Therapeutics Stock Is Sliding Despite Hype - TipRanks
KYMR: B. Riley Securities Raises Price Target for Kymera Therape - GuruFocus
B. Riley Raises Price Target on Kymera Therapeutics to $117 From $80, Keeps Buy Rating - marketscreener.com
Can Kymera Therapeutics Inc. stock hit analyst price targets2025 Valuation Update & Daily Growth Stock Tips - Улправда
Squarepoint Ops LLC Cuts Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
What momentum indicators show for Kymera Therapeutics Inc. stockDividend Hike & Low Risk Entry Point Guides - ulpravda.ru
Kymera Therapeutics (NASDAQ:KYMR) Shares Down 3.4%Here's What Happened - MarketBeat
Can Kymera Therapeutics Inc. stock deliver consistent earnings growth - Улправда
Kymera Therapeutics Insider Sold Shares Worth $2,264,480, According to a Recent SEC Filing - marketscreener.com
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs - 24/7 Wall St.
Why Analysts See Kymera Therapeutics Differently After KT 621 Momentum And Rising Fair Value - Yahoo Finance
RBC Capital Maintains Kymera Therapeutics (KYMR) Outperform Recommendation - Nasdaq
Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says - marketscreener.com
RBC Capital Raises Price Target for Kymera Therapeutics (KYMR) | - GuruFocus
RBC Raises Price Target on Kymera Therapeutics to $103 From $70, Keeps Outperform, Speculative Risk - marketscreener.com
Kymera Therapeutics stock price target raised to $103 from $70 at RBC Capital - Investing.com Canada
Kymera's eczema drug gets fast track designation in the United States - MSN
Obesity data, Kymera and FDA sentiment survey results — a BioCentury podcast - biocentury.com
Kymera gains fast track status for oral candidate KT-621 for eczema - MSN
Kymera Therapeutics Insider Sold Shares Worth $21,699,044, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. - Barron's
Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 678 Shares - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 6,101 Shares of Stock - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 229,809 Shares - MarketBeat
Eventide Asset Management LLC Increases Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
BVF Inc. IL Boosts Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics director Booth sells $21.7 million in stock By Investing.com - Investing.com Canada
Kymera Therapeutics director Booth sells $21.7 million in stock - Investing.com
0.80%
4.56%
大文字化:
|
ボリューム (24 時間):